AP NEWS

Apotheca Biosciences (PCFP) Overviews Pain-Patch, an Opioid Substitution

September 17, 2018

Saint Petersburg, FL, Sept. 17, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Apotheca Biosciences (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, drug formulations and cannabis delivery technologies for the healthcare and consumer care industry, announces the overview of its groundbreaking “Pain-Patch”.

Apotheca Biosciences has designed a groundbreaking patch to address major medical issues we face today. As we all know, the opiate crisis has become a significant issue resulting in sustained loss of life. Producing medicine, this loss of life factor cannot be acceptable. Pharmaceutical companies that launched opiates like Oxycontin stated the non-addictive nature of their “timed release” pills. What happens when these pills are crushed up and inhaled? Or having the opiate enter the body through the blood stream? The answer is simple, Oxycontin no longer becomes a timed-release drug and instead becomes a quick high. According to the National Institute on Drug abuse, more than 115 people a day die because of opiate overdose. This becomes a staggering number when considered as a global epidemic.

The problem with opiates stems from what it controls once taken in to the body. Under normal circumstances, our body produces endogenous neurotransmitters to block significant pain or reward us for processes like eating and reproduction. These receptors are found in the brain, spinal column, and across the body. Dependency starts when using heroin, oxycodone, or other morphine-derived drugs. These drugs flood the body with neurotransmitters, mainly dopamine, which is part of the body’s “reward” system. Once this process happens in the presynaptic neuron, increases in synaptic vesicles are observed and once the action potential travels to the synaptic cleft, the dopamine receptors receive a flood of dopamine in the postsynaptic neuron. This immediately causes a depolarization in the postsynaptic neuron and the cycle continues as the action potential travels down the next neuron.

Enough science, the bottom line is our bodies produce dopamine on a regular basis; if you produce too much (taking opiates) a short, extremely enjoyable feeling is observed. This process builds tolerance because the last paragraph discussed creating more dopamine receptors to take in more dopamine. Once this process happens, a dependency is formed, as more and more dopamine is required for the individual to feel “normal”. The scary part is opiates also control essential life functions like breathing: if too many opiates are taken, the individual can stop breathing.

According to MarketWatch, the opiate crisis is costing the U.S. $500 billion. Just the medical care alone needed for treatment of the afflicted amounts to approximately $28 billion. This is all according to MarketWatch. Extreme amounts of resources are being implemented in finding ways to create a better pain medication. Many companies are trying to capitalize on this right now, but these companies may not have what Apotheca Biosciences brings to the table. We know this because opiates are still being prescribed regularly.

We are introducing the “Pain-Patch” which is a safe and comfortable disposable patch system anyone can use. With the power of phytocannabinoids like cannabidiol (CBD) we can use the system our bodies have created hundreds of thousands of years ago. The Pain-Patch intends to deliver the safe medication directly to the brain stem, which helps cut off pain signaling from the peripheral nervous system to the central nervous system. The device is inexpensive to produce, and the disposable patches will be priced affordably.

References:

https://patents.google.com/patent/US6328992B1/en

https://link.springer.com/article/10.1007/s00415-012-6739-4

https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00368

http://www.mdpi.com/2305-6320/5/3/67

https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis

https://www.hhs.gov/opioids/about-the-epidemic/index.html

https://www.sciencedirect.com/science/article/pii/S0168365903004152

https://www.globalcannabinoids.io/cbd-transdermal-patches

https://hightimes.com/guides/transdermal-patches/

https://marysmedicinals.com/

If you would like more information on Apotheca’s products, please visit: www.apothecabiosciences.com/products-pipeline.

About Apotheca Biosciences Inc.

Apotheca is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Its pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its technologies to the world’s aging population.

To request further information about Apotheca, please email info@apothecabio.com, or visit its website at http://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact: Media Contact: (727) 228-3994 Apotheca Biosciences http://www.apothecabiosciences.com info@apothecabio.com Twitter - @apotheca Facebook – apotheca Telegram- apotheca

AP RADIO
Update hourly